产品封面图

雌激素受体α36抗体

收藏
  • ¥880 - 2480
  • gelatins
  • jlcR23769
  • 国内
  • 2025年07月13日
  • WB,ELISA等
  • 人/动物/植物
avatar
  • 企业认证

    点击 QQ 联系

  • 万千商家帮你免费找货

    0 人在求购买到急需产品
    • 详细信息
    • 询价记录
    • 文献和实验
    • 技术资料
    • 供应商

      江西江蓝纯生物试剂有限公司

    • 库存

      142

    • 克隆性

      单克隆

    • 保质期

      1年

    • 抗体英文名

      ER36

    • 抗体名

      雌激素受体α36抗体

    • 适应物种

      人/动物/植物

    • 应用范围

      WB,ELISA等

    • 浓度

      1mg/ml

    • 保存条件

      -20 °

    • 规格

      50ul/100ul/200ul

    规格:50ul产品价格:¥880.0
    规格:100ul产品价格:¥1580.0
    规格:200ul产品价格:¥2480.0
    产品 :  jlcR23769
    英文名称 :  ER36
    中文名称 : 雌激素受体α36抗体
        :  hER-alpha36, ER36, estrogen receptor isoform 4 .  
    研究领域 :  肿瘤  免疫学  生长因子和激素  内分泌病  
    抗体来源 :  Rabbit
    克隆类型 :  Polyclonal
    交叉反应  :  Human,
    产品应用 :  WB=1:500-2000 ELISA=1:500-1000 IHC-P=1:400-800 IHC-F=1:400-800 ICC=1:100-500 IF=1:100-500 (石蜡切片需做抗原修复)
    not yet tested in other applications.
    optimal dilutions/concentrations should be determined by the end user.
    :  67/36kDa
    细胞定位 :  细胞核 细胞浆 细胞膜
        :  Lyophilized or Liquid
        :  1mg/1ml
    :  KLH conjugated synthetic peptide derived from human ER36:271-310/310
        :  IgG
    纯化方法 :  affinity purified by Protein A
    :  0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
    保存条件 :  Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
    PubMed :  PubMed
    产品介绍 :   Estrogen and progesterone receptor are members of a family of transcription factors that are regulated by the binding of their cognate ligands. The interaction of hormone-bound estrogen receptors with estrogen responsive elements(EREs) alters transcription of ERE-containing genes. The carboxy terminal region of the estrgen receptor contains the ligand binding domain, the amino terminus serves as the transactivation domain, and the DNA binding domain is centrally located. Two forms of estrogen receptor have been identified, ER Alpha and ER Beta. ER Alpha and ER Beta have been shown to be differentially activated by various ligands. The biological response to progesterone is mediated by two distinct forms of the human progesterone receptor (hPR-A and hPR-B), which arise from alternative splicing. In most cells, hPR-B functions as a transcriptional activator of progesterone-responsive gene, whereas hPR-A function as a transcriptional inhibitor of all steroid hormone receptors.

    Function:
    Nuclear hormone receptor. The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Ligand-dependent nuclear transactivation involves either direct homodimer binding to a palindromic estrogen response element (ERE) sequence or association with other DNA-binding transcription factors, such as AP-1/c-Jun, c-Fos, ATF-2, Sp1 and Sp3, to mediate ERE-independent signaling. Ligand binding induces a conformational change allowing subsequent or combinatorial association with multiprotein coactivator complexes through LXXLL motifs of their respective components. Mutual transrepression occurs between the estrogen receptor (ER) and NF-kappa-B in a cell-type specific manner. Decreases NF-kappa-B DNA-binding activity and inhibits NF-kappa-B-mediated transcription from the IL6 promoter and displace RELA/p65 and associated coregulators from the promoter. Recruited to the NF-kappa-B response element of the CCL2 and IL8 promoters and can displace CREBBP. Present with NF-kappa-B components RELA/p65 and NFKB1/p50 on ERE sequences. Can also act synergistically with NF-kappa-B to activate transcription involving respective recruitment adjacent response elements; the function involves CREBBP. Can activate the transcriptional activity of TFF1. Also mediates membrane-initiated estrogen signaling involving various kinase cascades. Isoform 3 is involved in activation of NOS3 and endothelial nitric oxide production. Isoforms lacking one or several functional domains are thought to modulate transcriptional activity by competitive ligand or DNA binding and/or heterodimerization with the full length receptor. Isoform 3 can bind to ERE and inhibit isoform 1.

    Subunit:
    Binds DNA as a homodimer. Can form a heterodimer with ESR2. Isoform 3 can probably homodimerize or heterodimerize with isoform 1 and ESR2. Interacts with FOXC2, MAP1S, SLC30A9, UBE1C and NCOA3 coactivator. Interacts with EP300; the interaction is estrogen-dependent and enhanced by CITED1. Interacts with CITED1; the interaction is estrogen-dependent. Interacts with NCOA5 and NCOA6 coactivators. Interacts with NCOA7; the interaction is a ligand-inducible. Interacts with PHB2, PELP1 and UBE1C. Interacts with AKAP13. Interacts with CUEDC2. Interacts with KDM5A. Interacts with SMARD1. Interacts with HEXIM1. Interacts with PBXIP1. Interaction with MUC1 is stimulated by 7 beta-estradiol (E2) and enhances ERS1-mediated transcription. Interacts with DNTTIP2, FAM120B and UIMC1. Interacts with isoform 4 of TXNRD1. Interacts with MLL2. Interacts with ATAD2 and this interaction is enhanced by estradiol. Interacts with KIF18A and LDB1. Interacts with RLIM (via C-terminus). Interacts with MACROD1. Interacts with SH2D4A and PLCG. Interaction with SH2D4A blocks binding to PLCG and inhibits estrogen-induced cell proliferation. Interacts with DYNLL1. Interacts with CCDC62 in the presence of estradiol/E2; this interaction seems to enhance the transcription of target genes. Interacts with NR2C1; the interaction prevents homodimerization of ESR1 and suppresses its transcriptional activity and cell growth. Interacts with DYX1C1. Interacts with PRMT2. Interacts with PI3KR1 or PI3KR2, SRC and PTK2/FAK1. Interacts with RBFOX2. Interacts with STK3/MST2 only in the presence of SAV1 and vice-versa. Binds to CSNK1D. Interacts with NCOA2; NCOA2 can interact with ESE1 AF-1 and AF-2 domains simultaneously and mediate their transcriptional synergy. Interacts with DDX5. Interacts with NCOA1; the interaction seems to require a self-association of N-terminal and C-terminal regions. Interacts with ZNF366, DDX17, NFKB1, RELA, SP1 and SP3. Interacts with NRIP1.

    Subcellular Location:
    Isoform 1: Nucleus. Cytoplasm. Cell membrane; Peripheral membrane protein; Cytoplasmic side. Note=A minor fraction is associated with the inner membrane.
    Isoform 3: Nucleus. Cytoplasm. Cell membrane; Peripheral membrane protein; Cytoplasmic side. Cell membrane; Single-pass type I membrane protein. Note=Associated with the inner membrane via palmitoylation (Probable). At least a subset exists as a transmembrane protein with a N-terminal extracellular domain.
    Nucleus. Golgi apparatus. Cell membrane. Note=Colocalizes with ZDHHC7 and ZDHHC21 in the Golgi apparatus where most probably palmitoylation occurs. Associated with the plasma membrane when palmitoylated.

    Tissue Specificity:
    Widely expressed. Isoform 3 is not expressed in the pituitary gland.

    Post-translational modifications:
    Phosphorylated by cyclin A/CDK2 and CK1. Phosphorylation probably enhances transcriptional activity. Self-association induces phosphorylation.
    Glycosylated; contains N-acetylglucosamine, probably O-linked.
    Ubiquitinated. Deubiquitinated by OTUB1.
    Dimethylated by PRMT1 at Arg-260. The methylation may favor cytoplasmic localization.
    Palmitoylated (isoform 3). Not biotinylated (isoform 3).
    Palmitoylated by ZDHHC7 and ZDHHC21. Palmitoylation is required for plasma membrane targeting and for rapid intracellular signaling via ERK and AKT kinases and cAMP generation, but not for signaling mediated by the nuclear hormone receptor.

    Similarity:
    Belongs to the nuclear hormone receptor family. NR3 subfamily.
    Contains 1 nuclear receptor DNA-binding domain.

    SWISS:
    P03372

    Gene ID:
    2099

    Important Note:
    This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications.

    类固醇受体(Steroid Receptors

    产品图片
    产品细节图片1

    风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。

    • 作者
    • 内容
    • 询问日期
    图标文献和实验
    相关实验
    • 抗体夹心ELISA法检测待测样品sTNF-α含量

      抗体夹心ELISA法检测待测样品sTNF- α 含量   【基本原理】 选用两株针对TNF-α分子不同位点的单克隆抗体,即McAb1 (包被抗体)与McAb2 (酶标抗体)。先用McAb1 包被固相载体,使待测sTNF-α与之特异性结合,然后再加入辣根过氧化物酶(HRP)标记的McAb2 ,则形成McAb1 -sTNF-α -HRP标记McAb2 复合物,再加入HRP底物,则酶催化底物显色,测定样品与标准品光密度值(即OD值),绘制标准曲线,即可从标准曲线中

    • 抗体夹心ELISA法检测待测样品sTNF-α的含量

      实验试剂 1. 包被抗体McAb1 :使用时用包被液作适当稀释(如1:100)。 2. 酶标抗体McAb2 :以辣根过氧化物酶(HRP)标记。使用时用稀释液作适当稀释,其稀释度根据预试验结果而定。 3. rhuTNF-α标准品:已知含量的rhuTNF-(10ng/ml),使用时用稀释液作倍比稀释成7个浓度:5 ng/ml,2.5 ng/ml,1.25 ng/ml,625pg/ml,312 pg/ml,156 pg/ml

    • 单克隆抗体(McAb)亲和层析柱纯化重组人α2a干扰素(rHuIFN-α2a)

        重组人α干扰素作为一种具有广谱抗病毒、抑制肿瘤细胞生长及免疫调节作用的 细胞因子 新型药物,已在国内外广泛投入临床应用,并取得了显著的疗效。国际上对用于临床的重组干扰素的纯度要求很高,美国NIH规定必须在90%以上,因此生产者普遍采用亲和层析纯化法。我们研制了rHuIFN-α2a的McAb 3F1,与CNBr活化的Sepharose 4B交联制成亲和层析柱,经1年60余次较大规模试用表明具有较理想的亲和层析纯化rHuIFN-α2a的性能,达到

    图标技术资料

    暂无技术资料 索取技术资料

    同类产品报价

    产品名称
    产品价格
    公司名称
    报价日期
    ¥980
    温州科淼生物科技有限公司
    2025年07月12日询价
    ¥1080
    上海一研生物科技有限公司
    2025年07月05日询价
    ¥1180
    上海圻明生物科技有限公司
    2025年07月09日询价
    ¥1580
    上海钦诚生物科技有限公司
    2025年07月05日询价
    ¥2400
    深圳市豪地华拓生物科技有限公司
    2025年07月14日询价
    雌激素受体α36抗体
    ¥880 - 2480